clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT01523171 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | Canada | Q16 |
Spain | Q29 | ||
United States of America | Q30 | ||
Belgium | Q31 | ||
Italy | Q38 | ||
Austria | Q40 | ||
France | Q142 | ||
United Kingdom | Q145 | ||
Netherlands | Q55 | ||
Germany | Q183 | ||
P582 | end time | 2014-04-01 | |
P1050 | medical condition | chronic idiopathic myelofibrosis | Q3857106 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 97 | |
P8005 | research subject recruitment status | completed | Q76651189 |
P1813 | short name | JAKARTA2 | |
P859 | sponsor | Sanofi | Q158205 |
P580 | start time | 2012-04-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
Search more.